# Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction

Study · id `cardio:ct-nct06017609` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06017609](<https://clinicaltrials.gov/study/NCT06017609>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06017609

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 314 participants.

## Technical summary

Registry record NCT06017609. Randomized; quadruple masking; primary purpose treatment. Start 2023-12-20 (actual); primary completion 2026-05-18 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 314 participants (enrolled count; ClinicalTrials.gov record NCT06017609, source copy `cardio:ctgov-nct06017609-2026-09-24`, retrieved 2026-10-31)
- Started: 2023-12-20 (actual) (ClinicalTrials.gov record NCT06017609, source copy `cardio:ctgov-nct06017609-2026-09-24`, retrieved 2026-10-31)
- Primary completion: 2026-05-18 (actual) (ClinicalTrials.gov record NCT06017609, source copy `cardio:ctgov-nct06017609-2026-09-24`, retrieved 2026-10-31)
- Completion: 2026-05-18 (actual) (ClinicalTrials.gov record NCT06017609, source copy `cardio:ctgov-nct06017609-2026-09-24`, retrieved 2026-10-31)
- Countries: United States; Bulgaria; Czechia; Poland; Romania; Spain (ClinicalTrials.gov record NCT06017609, source copy `cardio:ctgov-nct06017609-2026-09-24`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06017609-2026-09-24`, retrieved 2026-10-31)

## The registry's words

- Brief title: Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction
- Acronym: POWER-HF
- Condition: Chronic Heart Failure
- Intervention (Drug): JTT-861 Capsules
- Intervention (Drug): Placebo Capsules
- Lead sponsor: Shionogi Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: ICON Clinical Research
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)

## Provenance

Content hash: ad432f8f0e685406fd14fb963d79994dec23e13e66d20d9dfe2831a9bd7c6c58
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
